Mass Tort Data Intelligence
Real-time docket tracking, filing velocity, and litigation intelligence across 50 active mass tort dockets.
Roundup: Bayer Seeks Approval of $7.25 Billion Settlement
At a September 14, 2026 hearing, Monsanto urged a Missouri judge to approve its proposed Roundup cancer settlement. The plan would provide up to $7.25 billion over as many as 21 years for qualifying current and future claims. Final approval was not confirmed in sources reviewed September 26.
Source: Bayer: September 14 settlement hearingPlaintiff Firm Rankings — Oct 21 – Nov 3, 2026
| # | Firm | City | Active Dockets | New | Leadership Status |
|---|---|---|---|---|---|
| 1 | Motley Rice LLC | Mt. Pleasant, SC | Social Media, AFFF, Talc | 45 | PSC — MDL 3047, MDL 2873 |
| 2 | Levin Papantonio Rafferty | Pensacola, FL | AFFF, Hair Relaxer, PowerPort | 38 | Co-Lead — MDL 2873 |
| 3 | Beasley Allen | Montgomery, AL | Paragard, Ozempic, Hair Relaxer | 32 | PSC — MDL 3094, MDL 2750 |
| 4 | Seeger Weiss LLP | New York, NY | Acetaminophen, FreeStyle Libre, Social Media | 30 | Co-Lead — MDL 3043 |
| 5 | Wisner Baum | Los Angeles, CA | Acetaminophen, Depo-Provera, Social Media | 28 | PSC — MDL 3043, MDL 3140 |
| 6 | Slater Slater Schulman | New York, NY | Uber, Lyft, Social Media | 25 | Lead — MDL 3084 |
| 7 | TorHoerman Law | Edwardsville, IL | Hair Relaxer, Paragard, Social Media | 22 | PSC — MDL 3060 |
| 8 | Weitz & Luxenberg | New York, NY | FreeStyle Libre, 1,4-Dioxane, Talc | 20 | PSC — MDL 2738 |
MDL Case Count Tracker — Oct 21 – Nov 3, 2026
50 dockets| Tort | MDL # | Total | New (Wk) | Trend | Key Development |
|---|---|---|---|---|---|
Tech | Pre-MDL | ~500+ | ~35 | FAST | State AG actions accelerating. Epic Games $520M FTC precedent. MDL formation expected 2026. |
Tech | 3047 | 10,000+ | ~30 | ACTIVE | AG claims resolved ($18B, Aug 26). Individual-injury docket post-Daubert; JCCP 5255 two-plaintiff trial v. Meta opened Oct 28. |
Talc / J&JBorderline Consumer | 2738 | 67,200+ | ~45 | FILING | CA $950M verdict vacated Mar 17. Continued high-volume filing. |
Hair RelaxerOpen Consumer | 3060 | ~15,100 | ~25 | ACTIVE | BELLWETHER SELECTION: Judge Rowland selected 3 cases Apr 1. |
Chemical | 2873 | 15,250+ | ~40 | FILING | Steady high-volume intake. Motley Rice, Levin Papantonio active. |
Device | 2846 | 23,800+ | ~50 | FILING | Continued largest filing volume. |
Depo-ProveraOpen Pharma | 3140 | 3,490+ | ~40 | FAST | Expert deps completed Mar 20. Preemption motion under advisement. |
Pharma | 3092 | ~8,500 | ~5 | FLAT | Bellwether discovery continues. |
Ozempic / GLP-1Open Pharma | 3094 | 3,546+ | ~20 | ACTIVE | Entering critical Daubert/SJ phase. |
Bard PowerPortOpen Device | 3081 | 3,044+ | ~40 | ACTIVE | TRIAL IMMINENT: Cook bellwether Apr 21. |
Paragard IUDBorderline Device | 2750 | 3,600+ | ~25 | FILING | Beasley Allen, TorHoerman active. Mediation ongoing. |
Ozempic NAIONOpen Pharma | 3163 | 73+ | ~19 | FAST | Separate MDL created Dec 2025. NJ MCL active in parallel. |
Pharma | 3043 | ~3,025 | ~25 | FILING | Seeger Weiss, Wisner Baum active. |
Tech | 3171 | ~170 | ~20 | FAST | Rapid intake continues. |
Tech | 3084 | 2,075+ | ~15 | FILING | Slater Slater Schulman active. |
Cartiva SCIOpen Device | 3172 | ~400 | ~10 | FILING | Mediation ongoing. Bellwether May 26. |
Dupixent CTCLOpen Pharma | 3180 | 18+ | ~5 | FAST | JPML MDL motion filed. Ruling expected soon. |
Nitrous OxideOpen Consumer | Pre-MDL | ~325 | ~25 | FAST | Pre-MDL. Multiple firms active. |
FreeStyle LibreOpen Device | Pre-MDL | ~215 | ~15 | FILING | Seeger Weiss, Weitz & Luxenberg active. |
1,4-DioxaneOpen Chemical | E.D.N.Y | 30+ | ~3 | FILING | Weitz & Luxenberg, Napoli Shkolnik active. |
ByHeart FormulaOpen Consumer | Pre-MDL | ~22 | ~4 | FILING | JPML Birmingham hearing Mar 26. Ruling imminent. |
Chemical | 2741 | 4,200+ | ~15 | ACTIVE | Bayer settlement ongoing. New cases still filing. |
Chemical | E.D.N.C. | 95,000+ | ~200 | FILING | PACT Act claims. Federal government defendant. |
Zantac / RanitidineClosed Pharma | 2924 | 2,100+ | ~2 | FLAT | Most claims dismissed. Science rulings unfavorable. |
ParaquatOpen Chemical | 3004 | 5,400+ | ~35 | FILING | Parkinson's disease link. Syngenta/Chevron defendants. |
Consumer | Pre-MDL | ~500 | ~20 | FAST | Emerging ovarian cancer claims separate from J&J. |
NEC Baby FormulaOpen Consumer | 3026 | 1,800+ | ~12 | ACTIVE | Abbott/Mead Johnson. Premature infant NEC claims. |
Pharma | 3043 | ~3,025 | ~25 | FILING | Autism/ADHD link. Retailers as defendants. |
TepezzaOpen Pharma | Pre-MDL | ~200 | ~10 | FAST | Hearing loss side effect. Horizon Therapeutics. |
Philips CPAPOpen Device | 3014 | 750+ | ~8 | ACTIVE | Foam degradation. Cancer risk claims. |
ElmironBorderline Pharma | 2973 | 1,200+ | ~3 | FLAT | Vision damage. Settlement discussions ongoing. |
Exactech ImplantOpen Device | 3044 | 900+ | ~10 | FILING | Polyethylene insert failures. |
BelviqOpen Pharma | Pre-MDL | ~150 | ~8 | FAST | Cancer risk. Pulled from market 2020. |
Chemical | Pre-MDL | ~400 | ~15 | FAST | PFAS exposure. Emerging litigation. |
Toxic Baby FoodOpen Consumer | Pre-MDL | ~300 | ~10 | FILING | Heavy metals in baby food. Multiple defendants. |
FluoroquinoloneBorderline Pharma | Pre-MDL | ~250 | ~2 | FLAT | Cipro/Levaquin. Peripheral neuropathy. |
Proton Pump InhibitorsClosed Pharma | 2789 | 12,000+ | ~5 | FLAT | Nexium/Prilosec. Kidney damage. Mostly settled. |
IVC FilterClosed Device | 2641 | 3,800+ | ~3 | FLAT | Bard/Cook. Filter migration/fracture. |
RisperdalClosed Pharma | 2767 | 900+ | ~2 | FLAT | Gynecomastia. Most cases resolved. |
3M EarplugsClosed Device | 2885 | Settled | 0 | FLAT | $6B settlement complete. Monitoring ongoing. |
ValsartanClosed Pharma | 2875 | 1,400+ | ~3 | FLAT | NDMA contamination. Cancer claims. |
Consumer | 3038 | 4,500+ | ~15 | ACTIVE | Youth vaping. School district claims. |
Other | Pre-MDL | ~50 | ~3 | FAST | Antitrust. PGA merger implications. |
Tech | Pre-MDL | ~100 | ~5 | FILING | Driver-on-passenger assault claims. |
WeChat PrivacyOpen Tech | Pre-MDL | ~75 | ~4 | FAST | Data privacy violations. CCPA claims. |
Monsanto PCBOpen Chemical | 2342 | 2,500+ | ~10 | FILING | Environmental contamination. School claims. |
Consumer | 2738 | Part of Talc | ~20 | FILING | Subset of Talc MDL. |
Pharma | Pre-MDL | ~100 | ~5 | FAST | Autoimmune injury claims. Merck defendant. |
Metal-on-Metal HipClosed Device | 2244 | 4,000+ | ~2 | FLAT | DePuy/Stryker. Mostly resolved. |
Pharma | Pre-MDL | ~50 | ~3 | FAST | Immune-related organ failure. Merck defendant. |
Critical Dates — Next 60 Days
12 events| Date | Docket | Event | Investor Significance |
|---|---|---|---|
| Nov 9, 2026 | Camp Lejeune Litigation (E.D.N.C.) | First kidney cancer Track 1 bench trial (Mousser) before Judge Boyle — sources conflict (Oct 27 vs Nov 9 vs Nov 16 for Mousser/Fancher); unconfirmed | First Track 1 trial outcomes would set value benchmarks across roughly 95,000 pending claims. |
| Nov 10, 2026 | Social Media JCCP 5255 | Meta CEO Mark Zuckerberg tentatively expected to testify in the S.J./K.D.B. bellwether before Judge Kuhl (tentative per Daily Journal) | Executive testimony raises verdict and settlement pressure on Meta in the first post-multistate-deal PI trial. |
| Nov 16, 2026 | Hair Relaxer MDL 3060 | Bellwether expert discovery closes (Judge Rowland, N.D. Ill.) | Gates dispositive motions due Dec 16; first trials now projected 2027 |
| Nov 16, 2026 | Camp Lejeune Litigation (E.D.N.C.) | Next in-person hearing in Wilmington per late-reporting trackers (unconfirmed against a court order) | Checkpoint on Track 1 trial sequencing and global settlement progress after the Oct 30 target. |
| Nov 17, 2026 | Ozempic MDL 3094 | Status conference before Judge Marston (E.D. Pa.) | Second post-Daubert-hearing checkpoint; ruling on general causation could land before or at this conference |
| Nov 19, 2026 | Social Media JCCP 5255 | Instagram head Adam Mosseri tentatively scheduled to testify before Judge Kuhl (tentative) | Second senior-executive witness; timing signals trial length and likely jury submission date. |
| Nov 19, 2026 | J&J Talc MDL 2738 | Plaintiffs' 90-day response deadline to Judge Singh's July 22 specific-causation order to show cause | Determines whether non-settling claims survive the withdrawn-expert problem; runs alongside the 95%-participation threshold on the $5.5B+ deal |
| Nov 20, 2026 | AFFF MDL 2873 | Proposals due for selecting Group B personal-injury bellwether cases (thyroid disease, ulcerative colitis) — Judge Gergel (D.S.C.) | Only live PI milestone after the Oct 2025 kidney-cancer trial was vacated; shapes when a first PI trial can be set |
| Nov 30, 2026 | Depo-Provera MDL 3140 | Firm registration deadline for the Pfizer master settlement (Judge Rodgers' Aug 10 order; BrownGreer administering) | Irrevocable enrollment cutoff; ~80% of eligible plaintiffs expected to qualify; payments begin Q1 2027 |
| Dec 1, 2026 | Bard PowerPort MDL 3081 | Hicks bellwether trial begins (set Dec 1–21 under First Amended CMO 50) | Third jury test in four months; outcome likely triggers global settlement talks |
| Dec 15, 2026 | Ozempic MDL 3094 | Status conference before Judge Marston (E.D. Pa.) | Year-end checkpoint; if Daubert is decided by then, bellwether selection follows |
| Dec 16, 2026 | Hair Relaxer MDL 3060 | Case-specific summary-judgment and expert-admissibility motions due, Judge Rowland (proposed, unconfirmed; one tracker lists Nov 16 instead) | First case-specific dispositive motions ahead of the Sept 7, 2027 first bellwether trial. |
New Filings — Oct 21 – Nov 3, 2026
| Case | Defendant | Court | Theory | Lead Firm |
|---|---|---|---|---|
| Rodriguez v. Meta Platforms | Meta Platforms, Inc. | N.D. Cal. | Product liability — algorithmic addiction | Motley Rice LLC |
| Thompson v. Bard Medical | Bard Medical / BD | D. Ariz. | Device failure — catheter fracture | Levin Papantonio |
| Williams v. Pfizer Inc. | Pfizer Inc. | S.D.N.Y. | Failure to warn — Depo-Provera meningioma | Wisner Baum |
| Garcia v. Novo Nordisk | Novo Nordisk A/S | E.D. Pa. | GLP-1 gastroparesis / bowel obstruction | Beasley Allen |
| Davis v. Lyft, Inc. | Lyft, Inc. | N.D. Cal. | Negligent hiring — sexual assault | Slater Slater Schulman |
| Chen v. Abbott Labs | Abbott Laboratories | N.D. Ill. | Device defect — FreeStyle Libre burns | Seeger Weiss LLP |
Analyst Notes & Portfolio Strategy
Priority assessments, stage analysis, and portfolio positioning across active mass tort dockets.
Analyst Notes — Investor Outlook
Social Media Youth Addiction
Elevated PriorityThe NM verdict fundamentally shifts the litigation landscape. Federal bellwether on June 15 is the next major catalyst. Expect heightened settlement pressure on Meta/Google. Monitor appellate timeline closely — a sustained verdict dramatically increases portfolio exposure.
Talc / J&J
Bankruptcy WatchThird prepackaged bankruptcy attempt (June 2 hearing) remains the central variable. CA verdict vacation adds complexity. Resolution of 67K+ claims hinges on bankruptcy court approval of $8.9B trust proposal.
Hair Relaxer
Trial PreparationBellwether selections signal active progression. Three cases chosen April 1 will define trial strategy. L'Oreal, Revlon exposure significant. Watch for Daubert rulings on causation experts in coming weeks.
Depo-Provera
Elevated PriorityPreemption ruling (expected May 5) is threshold issue. If denied, rapid case growth likely accelerates. Pfizer exposure could be substantial given long market history and meningioma causation evidence.
Ozempic / GLP-1
Critical JunctureMay 12 Daubert hearing is make-or-break. Favorable ruling opens massive liability exposure for Novo Nordisk and Eli Lilly. Unfavorable ruling could significantly deflate docket. High-stakes binary outcome.
Bard PowerPort
Trial ImminentCook Medical bellwether (April 21) is the first catheter port trial. Outcome will set settlement benchmarks. BD/Bard cases to follow. Device failure evidence is strong — favorable plaintiff verdict expected.
Opportunities by Stage
Early signals. Pre-MDL formation. First-mover window.
Active investigation. Firms building inventory.
Post-Daubert. Bellwethers and trial-by-trial.
Settlement pressure. Global deal in motion.
The Diversified Core Portfolio
8 curated mass tort positions across 5 sectors and 4 stages.
Don't miss a ruling, verdict, or filing.
Every Monday: critical docket developments, filing velocity changes, bellwether outcomes, and portfolio signals — in one email.
Upload expert documents into the live docket board
Upload litigation reports, filings, or normalized JSON. Trusted docket facts become homepage overrides when they match a live MDL or tracked docket.